Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1990 1
1991 3
1992 4
1997 1
1998 1
1999 1
2000 1
2001 1
2002 1
2003 1
2005 1
2008 1
2009 1
2011 1
2012 1
2013 2
2014 2
2015 1
2018 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody.
Wang EQ, Kaila N, Plowchalk D, Gibiansky L, Yunis C, Sweeney K. Wang EQ, et al. Among authors: plowchalk d. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):2013-2026. doi: 10.1002/psp4.13050. Epub 2023 Nov 22. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37994400 Free PMC article.
An EP2 receptor-selective prostaglandin E2 agonist induces bone healing.
Paralkar VM, Borovecki F, Ke HZ, Cameron KO, Lefker B, Grasser WA, Owen TA, Li M, DaSilva-Jardine P, Zhou M, Dunn RL, Dumont F, Korsmeyer R, Krasney P, Brown TA, Plowchalk D, Vukicevic S, Thompson DD. Paralkar VM, et al. Among authors: plowchalk d. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6736-40. doi: 10.1073/pnas.1037343100. Epub 2003 May 14. Proc Natl Acad Sci U S A. 2003. PMID: 12748385 Free PMC article.
Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.
Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM. Vieira ML, et al. Among authors: plowchalk d. Clin Pharmacol Ther. 2014 Feb;95(2):189-98. doi: 10.1038/clpt.2013.187. Epub 2013 Sep 18. Clin Pharmacol Ther. 2014. PMID: 24048277
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, Sweeney K, Kaila N, Vincent J, Bays H. Ballantyne CM, et al. Among authors: plowchalk d. Am J Cardiol. 2015 May 1;115(9):1212-21. doi: 10.1016/j.amjcard.2015.02.006. Epub 2015 Feb 12. Am J Cardiol. 2015. PMID: 25784512 Free article. Clinical Trial.
27 results